Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment
Claus Garbe(University of Tübingen), Christos C. Zouboulis(Freie Universität Berlin), John M. Kirkwood(UPMC Hillman Cancer Center), Jochen Utikal(German Cancer Research Center), Olivier Michielin(SIB Swiss Institute of Bioinformatics), Anja Gesierich(University of Michigan), Ulrike Keim, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Uwe Wollina(Städtisches Klinikum Dresden), Cord Sunderkötter(MSB Medical School Berlin), Axel Hauschild(University Hospital Schleswig-Holstein), Alexander M.M. Eggermont(University Medical Center Utrecht), Teresa Amaral(University Children's Hospital Tübingen), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Jean‐Jacques Grob(Aix-Marseille Université), Jason J. Luke(University of Chicago), Lisa Zimmer(The University of Sydney), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Lidija Kandolf Sekulović(Military Medical Academy), Thomas Tüting(Otto-von-Guericke-Universität Magdeburg), Ulrike Leiter(University of Tübingen), Lukas Flatz(Leman University), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Ketty Peris(Università Cattolica del Sacro Cuore)
Cited by 108
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k